Abstract
Objective
Postoperative radiotherapy (RT) is an established treatment for prostate cancer (PC). Though hypofractionation is commonly used for radical treatments, open issues still remain in the postoperative setting due to the lack of long-term data. Aim of this study was to evaluate long-term results of postoperative moderately hypofractionated RT (MHRT).
Methods
We conducted a retrospective analysis including PC patients treated with prostatectomy and postoperative MHRT delivered with volumetric modulated arc therapy (VMAT). Endpoints of the analysis included biochemical relapse-free survival (BRFS), distant metastases free-survival (DMFS), overall survival (OS), and pattern of acute and late toxicity.
Results
181 patients were included. Pathological stage was classified as pT3a in 33.6% and pT3b in 30%. Median PSA value before RT was 0.23 ng/ml and median RT total dose was 70 Gy (65–74.2 Gy) in 25/28 fractions. With a median follow-up of 54.5 months, rates of BRFS at 3 and 5 years were 80.7 and 72.3%. ISUP grade group (HR 1.44, p = 0.015), pathological T stage (HR 2.03; p = 0.009), and pre-RT PSA >0.2 ng/ml (HR 2.64; p = 0.015) were correlated with BRFS. Three and 5‑year DMFS were 87.4 and 80.8%. ISUP grade group (HR 1.50; p = 0.011) and pre-RT PSA (HR 5.34; p = 0.001) were correlated with DMFS. Five (2.7%) and 3 (1.6%) patients reported late grade 3 GU and GI toxicity, respectively.
Conclusion
Our results confirm the long-term safety and efficacy of postoperative MHRT for PC.
Advances in knowledge
The present paper demonstrates the long-term safety and efficacy of MHRT for postoperative prostate cancer. Reduction of treatment time in long-course radiotherapy has advantages in terms of both patients’ quality of life and departmental organization.
Similar content being viewed by others
References
Schröder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328. https://doi.org/10.1056/NEJMoa0810084
National Comprehensive Cancer Network (2019) NCCN clinical practice guidelines in oncology: prostate cancer 2019. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
Thompson IM, Tangen CM, Paradelo J et al (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. J Am Med Assoc 296(19):2329–2335. https://doi.org/10.1001/jama.296.19.2329
Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27(18):2924–2930. https://doi.org/10.1200/JCO.2008.18.9563
Bolla M, van Poppel H, Tombal B et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380(9858):2018–2027. https://doi.org/10.1016/S0140-6736(12)61253-7
Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43(5):1095–1101. https://doi.org/10.1016/S0360-3016(98)00438-6
Fowler J, Chappell R, Ritter M (2001) Is α/β for prostate tumors really low? Int J Radiat Oncol Biol Phys 50(4):1021–1031. https://doi.org/10.1016/S0360-3016(01)01607-8
Dearnaley D, Syndikus I, Mossop H et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5‑year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17(8):1047–1060. https://doi.org/10.1016/S1470-2045(16)30102-4
Lee WR, Dignam JJ, Amin MB et al (2016) Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 34(20):2325–2332. https://doi.org/10.1200/JCO.2016.67.0448
Michalski JM, Lawton C, El Naqa I et al (2010) Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 76(2):361–368. https://doi.org/10.1016/j.ijrobp.2009.02.006
Fossati N, Karnes RJ, Boorjian SA et al (2017) Long-term impact of adjuvant versus early salvage radiation therapy in pT3N0 prostate cancer patients treated with radical prostatectomy: results from a multi-institutional series. Eur Urol 71(6):886–893. https://doi.org/10.1016/j.eururo.2016.07.028
Briganti A, Wiegel T, Joniau S et al (2012) Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol 62(3):472–487. https://doi.org/10.1016/j.eururo.2012.04.056
Ost P, De Troyer B, Fonteyne V, Oosterlinck W, De Meerleer G (2011) A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 80(5):1316–1322. https://doi.org/10.1016/j.ijrobp.2010.04.039
Hwang WL, Tendulkar RD, Niemierko A et al (2018) Comparison between adjuvant and early-salvage postprostatectomy radiotherapy for prostate cancer with adverse pathological features. JAMA Oncol 4(5):e175230. https://doi.org/10.1001/jamaoncol.2017.5230
Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25(15):2035–2041. https://doi.org/10.1200/JCO.2006.08.9607
Tendulkar RD, Agrawal S, Gao T et al (2016) Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. j Clin Oncol 34(30):3648–3654. https://doi.org/10.1200/JCO.2016.67.9647
Lee LW, McBain CA, Swindell R, Wylie JP, Cowan RA, Logue JP (2004) Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy. Clin Oncol 16(8):517–522. https://doi.org/10.1016/j.clon.2004.07.006
Koukourakis MI, Papadopoulou A, Abatzoglou I, Panteliadou M, Sismanidou K, Touloupidis S (2012) Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer. Anticancer Res 32(10):4561–4568
Kruser TJ, Jarrard DF, Graf AK et al (2011) Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer 117(12):2629–2636. https://doi.org/10.1002/cncr.25824
Fersino S, Tebano U, Mazzola R et al (2017) Moderate hypofractionated postprostatectomy volumetric modulated arc therapy with daily image guidance (VMAT-IGRT): a mono-institutional report on feasibility and acute toxicity. Clin Genitourin Cancer 15(4):e667–e673. https://doi.org/10.1016/j.clgc.2017.01.025
Syndikus I, Pickles TKE et al (1996) Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. J Urol 155:1983–1986
Cozzarini C, Fiorino C, Deantoni C et al (2014) Higher-than-expected severe (grade 3–4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur Urol 66(6):1024–1030. https://doi.org/10.1016/j.eururo.2014.06.012
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
C. Franzese, M. Badalamenti, D. Baldaccini, G. D’Agostino, T. Comito, D. Franceschini, E. Clerici, P. Navarria, G. Reggiori, S. Tomatis, and M. Scorsetti declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Franzese, C., Badalamenti, M., Baldaccini, D. et al. Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity. Strahlenther Onkol 197, 133–140 (2021). https://doi.org/10.1007/s00066-020-01691-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-020-01691-z